Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H17ClN6O2 |
| Molecular Weight | 396.83 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CN1C=CC(=N1)C2=CC(Cl)=C(C=C2)C#N)NC(=O)C3=NNC(=C3)C(C)=O
InChI
InChIKey=GMBPVBVTPBWIKC-NSHDSACASA-N
InChI=1S/C19H17ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-/m0/s1
| Molecular Formula | C19H17ClN6O2 |
| Molecular Weight | 396.83 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26137992
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26137992
ORM-15341 is an active main metabolite of ODM-201, which is structurally distinct from any known antiandrogens including the second-generation antiandrogens enzalutamide. ORM-15341 is a potent and full antagonist for human androgen receptor. It was shown, that in VCaP prostate cancer cells containing endogenous AR gene amplification and overexpressing AR, ORM-15341 inhibited cell proliferation more efficiently than enzalutamide or ARN-509.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26313416
Curator's Comment: Known to be CNS non-penetrant in mouse. Human data not available
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26137992 |
38.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. | 2015-07-03 |
|
| ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. | 2015 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26313416
HepaRG cells were treated with 10 μM of ORM-15341
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:21:54 GMT 2025
by
admin
on
Tue Apr 01 16:21:54 GMT 2025
|
| Record UNII |
9EPS75QMTL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID101111196
Created by
admin on Tue Apr 01 16:21:54 GMT 2025 , Edited by admin on Tue Apr 01 16:21:54 GMT 2025
|
PRIMARY | |||
|
9EPS75QMTL
Created by
admin on Tue Apr 01 16:21:54 GMT 2025 , Edited by admin on Tue Apr 01 16:21:54 GMT 2025
|
PRIMARY | |||
|
52919826
Created by
admin on Tue Apr 01 16:21:54 GMT 2025 , Edited by admin on Tue Apr 01 16:21:54 GMT 2025
|
PRIMARY | |||
|
1297537-33-7
Created by
admin on Tue Apr 01 16:21:54 GMT 2025 , Edited by admin on Tue Apr 01 16:21:54 GMT 2025
|
PRIMARY | |||
|
DB15647
Created by
admin on Tue Apr 01 16:21:54 GMT 2025 , Edited by admin on Tue Apr 01 16:21:54 GMT 2025
|
PRIMARY | |||
|
Ketodarolutamide
Created by
admin on Tue Apr 01 16:21:54 GMT 2025 , Edited by admin on Tue Apr 01 16:21:54 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
Ki
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|